[
  {
    "name": "ramipril",
    "tags": ["cardio", "renal", "safety"],
    "anchors": [
      {
        "id": "class",
        "title": "Drug class",
        "prompt": "Which class does ramipril belong to?",
        "type": "single",
        "options": [
          { "id": "ace", "label": "ACE inhibitor" },
          { "id": "arb", "label": "Angiotensin II receptor blocker (ARB)" },
          { "id": "ccb", "label": "Dihydropyridine calcium-channel blocker" },
          { "id": "bb",  "label": "β-blocker" },
          { "id": "renin", "label": "Direct renin inhibitor" }
        ],
        "correct": ["ace"],
        "explanation": "Ramipril is an ACE inhibitor (prodrug → ramiprilat). ARBs block AT1 receptors (not ACE); CCBs and β-blockers are different classes; aliskiren is the direct renin inhibitor."
      },
      {
        "id": "indications",
        "title": "Common indications",
        "prompt": "Select ALL common indications for ramipril.",
        "type": "multi",
        "options": [
          { "id": "htn", "label": "Hypertension" },
          { "id": "hfref", "label": "Heart failure with reduced ejection fraction" },
          { "id": "postmi", "label": "Post-MI / secondary prevention" },
          { "id": "ckdprot", "label": "CKD with albuminuria (including diabetic nephropathy)" },
          { "id": "angina", "label": "Stable angina treatment" },
          { "id": "asthma", "label": "Asthma maintenance therapy" }
        ],
        "correct": ["htn", "hfref", "postmi", "ckdprot"],
        "explanation": "ACE inhibitors are core therapy for HTN, HFrEF, post-MI remodeling/risk reduction, and renoprotection in albuminuric CKD. They are not first-line angina anti-ischaemics and have no role in asthma."
      },
      {
        "id": "moa",
        "title": "Mechanism of action",
        "prompt": "Which best describes ramipril’s mechanism?",
        "type": "single",
        "options": [
          { "id": "true", "label": "Inhibits ACE → ↓Ang II and ↓aldosterone; ↑bradykinin → vasodilation" },
          { "id": "arbmech", "label": "Blocks AT1 receptors (ARB)" },
          { "id": "ccbmech", "label": "Blocks L-type Ca²⁺ channels in vascular smooth muscle" },
          { "id": "reninmech", "label": "Directly inhibits renin" }
        ],
        "correct": ["true"],
        "explanation": "ACE inhibition reduces angiotensin II and aldosterone and increases bradykinin, producing vasodilation and natriuresis."
      },
      {
        "id": "adrs",
        "title": "Important adverse reactions",
        "prompt": "Select ALL clinically important adverse reactions of ramipril.",
        "type": "multi",
        "options": [
          { "id": "cough", "label": "Dry cough" },
          { "id": "angio", "label": "Angioedema" },
          { "id": "hyperk", "label": "Hyperkalaemia" },
          { "id": "hypot", "label": "Symptomatic hypotension" },
          { "id": "creat", "label": "Rise in creatinine/AKI risk" },
          { "id": "gingival", "label": "Gingival hyperplasia" }
        ],
        "correct": ["cough", "angio", "hyperk", "hypot", "creat"],
        "explanation": "Cough/angioedema from bradykinin; hyperkalaemia and creatinine rise due to reduced efferent arteriolar tone; first-dose hypotension possible. Gingival hyperplasia is typical of nifedipine (CCB), not ACEIs."
      },
      {
        "id": "interactions",
        "title": "Important drug–drug interactions",
        "prompt": "Select ALL clinically important interactions with ramipril.",
        "type": "multi",
        "options": [
          { "id": "kplus", "label": "Potassium supplements or K-sparing diuretics (e.g., spironolactone)" },
          { "id": "nsaids", "label": "Chronic NSAIDs" },
          { "id": "lithium", "label": "Lithium" },
          { "id": "dualraas", "label": "Dual RAAS blockade (ARB/aliskiren)" },
          { "id": "ppi", "label": "Proton-pump inhibitors" },
          { "id": "macrolide", "label": "Macrolide antibiotics" }
        ],
        "correct": ["kplus", "nsaids", "lithium", "dualraas"],
        "explanation": "K-raising agents ↑hyperkalaemia risk; NSAIDs blunt antihypertensive/renoprotective effect and ↑AKI risk; ACEIs ↑lithium concentrations; avoid dual RAAS blockade. PPIs/macrolides are not typical interaction problems."
      }
    ]
  },
  {
    "name": "atorvastatin",
    "tags": ["cardio", "lipids"],
    "anchors": [
      {
        "id": "class",
        "title": "Drug class",
        "prompt": "Which class does atorvastatin belong to?",
        "type": "single",
        "options": [
          { "id": "statin", "label": "HMG-CoA reductase inhibitor (statin)" },
          { "id": "ezet",  "label": "Cholesterol absorption inhibitor (ezetimibe)" },
          { "id": "pcsk9", "label": "PCSK9 inhibitor" },
          { "id": "ace",   "label": "ACE inhibitor" },
          { "id": "ccb",   "label": "Calcium-channel blocker" }
        ],
        "correct": ["statin"],
        "explanation": "Atorvastatin is a statin; the others are different lipid or cardiovascular classes."
      },
      {
        "id": "indications",
        "title": "Common indications",
        "prompt": "Select ALL appropriate indications for atorvastatin.",
        "type": "multi",
        "options": [
          { "id": "primary", "label": "Primary hypercholesterolaemia" },
          { "id": "fh", "label": "Familial hypercholesterolaemia (adjunct/first-line depending on severity)" },
          { "id": "cvprev", "label": "Cardiovascular risk reduction / secondary prevention" },
          { "id": "angina", "label": "Symptom relief in stable angina" },
          { "id": "pain", "label": "Analgesia" }
        ],
        "correct": ["primary", "fh", "cvprev"],
        "explanation": "Statins lower LDL and reduce CV events for primary/secondary prevention and in familial hypercholesterolaemia. They are not for immediate angina symptom relief and are not analgesics."
      },
      {
        "id": "moa",
        "title": "Mechanism of action",
        "prompt": "Which statement best describes atorvastatin’s mechanism?",
        "type": "single",
        "options": [
          { "id": "true", "label": "Inhibits HMG-CoA reductase → ↓hepatic cholesterol synthesis; ↑LDL receptors" },
          { "id": "ace", "label": "Inhibits ACE to reduce Ang II" },
          { "id": "ccb", "label": "Blocks L-type Ca²⁺ channels" },
          { "id": "upregOnly", "label": "Only upregulates hepatic LDL receptors without affecting synthesis" }
        ],
        "correct": ["true"],
        "explanation": "Primary action is enzyme inhibition; LDL-receptor upregulation is a downstream effect. The other mechanisms are unrelated."
      },
      {
        "id": "adrs",
        "title": "Important adverse reactions",
        "prompt": "Select ALL clinically important adverse reactions of atorvastatin.",
        "type": "multi",
        "options": [
          { "id": "myopathy", "label": "Myalgia/myopathy (rare rhabdomyolysis)" },
          { "id": "lfts", "label": "↑Transaminases/hepatotoxicity" },
          { "id": "gi", "label": "GI upset" },
          { "id": "dm", "label": "Slight increase in diabetes risk" },
          { "id": "cough", "label": "Dry cough" },
          { "id": "ankleEdema", "label": "Ankle oedema" }
        ],
        "correct": ["myopathy", "lfts", "gi", "dm"],
        "explanation": "Muscle symptoms and LFT elevation are the key concerns; GI upset is common; there is a small increase in diabetes risk. Dry cough is typical of ACEIs; ankle oedema is more typical with dihydropyridine CCBs."
      },
      {
        "id": "interactions",
        "title": "Important drug–drug interactions",
        "prompt": "Select ALL clinically important interactions with atorvastatin.",
        "type": "multi",
        "options": [
          { "id": "cyp3a4", "label": "Strong CYP3A4 inhibitors (e.g., clarithromycin, azoles, HIV protease inhibitors)" },
          { "id": "gfj", "label": "Grapefruit juice (large amounts)" },
          { "id": "fibrates", "label": "Fibrates (e.g., gemfibrozil)" },
          { "id": "warfarin", "label": "Warfarin" },
          { "id": "acei", "label": "ACE inhibitors" }
        ],
        "correct": ["cyp3a4", "gfj", "fibrates"],
        "explanation": "CYP3A4 inhibitors and grapefruit increase statin levels → ↑myopathy risk; fibrates further increase myopathy risk. Warfarin/ACEIs are not primary interaction concerns for atorvastatin."
      }
    ]
  },
  {
    "name": "bisoprolol",
    "tags": ["cardio"],
    "anchors": [
      {
        "id": "class",
        "title": "Drug class",
        "prompt": "Which class does bisoprolol belong to?",
        "type": "single",
        "options": [
          { "id": "bb1", "label": "β1-selective β-blocker" },
          { "id": "ccb", "label": "Calcium-channel blocker" },
          { "id": "ace", "label": "ACE inhibitor" },
          { "id": "loop", "label": "Loop diuretic" },
          { "id": "arb", "label": "Angiotensin II receptor blocker (ARB)" }
        ],
        "correct": ["bb1"],
        "explanation": "Bisoprolol is a cardioselective (β1-predominant) β-blocker."
      },
      {
        "id": "indications",
        "title": "Common indications",
        "prompt": "Select ALL appropriate indications for bisoprolol.",
        "type": "multi",
        "options": [
          { "id": "htn", "label": "Hypertension (adjunct/alternative)" },
          { "id": "angina", "label": "Stable angina (anti-ischaemic)" },
          { "id": "hfref", "label": "Heart failure with reduced EF (evidence-based)" },
          { "id": "afRate", "label": "Rate control in atrial fibrillation" },
          { "id": "asthma", "label": "Asthma prophylaxis" },
          { "id": "migraine", "label": "Migraine prophylaxis" }
        ],
        "correct": ["htn", "angina", "hfref", "afRate"],
        "explanation": "Used across HTN/angina/HFrEF and AF rate control. Avoid in asthma (bronchospasm); bisoprolol is not a standard choice for migraine prophylaxis compared with propranolol."
      },
      {
        "id": "moa",
        "title": "Mechanism of action",
        "prompt": "Which best describes bisoprolol’s mechanism?",
        "type": "single",
        "options": [
          { "id": "true", "label": "Blocks cardiac β1-adrenergic receptors → ↓HR/contractility and ↓renin release" },
          { "id": "thiazide", "label": "Inhibits Na⁺/Cl⁻ cotransporter in the distal convoluted tubule" },
          { "id": "ccbmech", "label": "Blocks L-type Ca²⁺ channels" },
          { "id": "acei", "label": "Inhibits ACE to reduce Ang II" }
        ],
        "correct": ["true"],
        "explanation": "β1 blockade reduces chronotropy/inotropy and renin secretion. The other options are distinct mechanisms."
      },
      {
        "id": "adrs",
        "title": "Important adverse reactions",
        "prompt": "Select ALL clinically important adverse reactions of bisoprolol.",
        "type": "multi",
        "options": [
          { "id": "brady", "label": "Bradycardia/AV block" },
          { "id": "fatigue", "label": "Fatigue, exercise intolerance" },
          { "id": "bronch", "label": "Bronchospasm (esp. in asthma/COPD)" },
          { "id": "cold", "label": "Cold extremities" },
          { "id": "sex", "label": "Sexual dysfunction" },
          { "id": "cough", "label": "Persistent dry cough" }
        ],
        "correct": ["brady", "fatigue", "bronch", "cold", "sex"],
        "explanation": "Typical β-blocker effects: bradyarrhythmia, fatigue, bronchospasm (loss of β2-mediated bronchodilation), cold peripheries, sexual dysfunction. Dry cough is characteristic of ACE inhibitors, not β-blockers."
      },
      {
        "id": "interactions",
        "title": "Important drug–drug interactions",
        "prompt": "Select ALL clinically important interactions with bisoprolol.",
        "type": "multi",
        "options": [
          { "id": "verap", "label": "Non-DHP CCBs (verapamil/diltiazem)" },
          { "id": "dig", "label": "Digoxin" },
          { "id": "clon", "label": "Clonidine (abrupt withdrawal)" },
          { "id": "amio", "label": "Amiodarone" },
          { "id": "nitrates", "label": "Organic nitrates" }
        ],
        "correct": ["verap", "dig", "clon", "amio"],
        "explanation": "Additive AV-nodal depression with non-DHP CCBs, digoxin, and amiodarone; clonidine withdrawal can cause rebound hypertension exacerbated by β-blockade. Nitrates are generally safe with β-blockers."
      }
    ]
  },
  {
    "name": "metformin",
    "tags": ["endocrine"],
    "anchors": [
      {
        "id": "class",
        "title": "Drug class",
        "prompt": "Which class does metformin belong to?",
        "type": "single",
        "options": [
          { "id": "big", "label": "Biguanide" },
          { "id": "sulf", "label": "Sulfonylurea" },
          { "id": "dpp4", "label": "DPP-4 inhibitor" },
          { "id": "sglt2", "label": "SGLT2 inhibitor" }
        ],
        "correct": ["big"],
        "explanation": "Metformin is a biguanide; it is not a secretagogue (sulfonylurea) nor DPP-4/SGLT2 inhibitor."
      },
      {
        "id": "indications",
        "title": "Common indications",
        "prompt": "Select ALL appropriate indications for metformin.",
        "type": "multi",
        "options": [
          { "id": "t2dm", "label": "Type 2 diabetes mellitus (first-line)" },
          { "id": "pcos", "label": "Polycystic ovary syndrome (insulin resistance; off-label/common practice)" },
          { "id": "t1dm", "label": "Type 1 diabetes mellitus" },
          { "id": "dka", "label": "Diabetic ketoacidosis treatment" },
          { "id": "obesityOnly", "label": "Weight loss in euglycaemic patients (sole indication)" }
        ],
        "correct": ["t2dm", "pcos"],
        "explanation": "First-line for T2DM and commonly used for PCOS-related insulin resistance. It is not used for T1DM alone, not for DKA, and not as a stand-alone obesity drug in euglycaemia."
      },
      {
        "id": "moa",
        "title": "Mechanism of action",
        "prompt": "Which best describes metformin’s mechanism?",
        "type": "single",
        "options": [
          { "id": "true", "label": "Activates AMPK → ↓hepatic gluconeogenesis; ↑peripheral glucose uptake" },
          { "id": "ins", "label": "Stimulates pancreatic insulin release" },
          { "id": "sglt2mech", "label": "Inhibits renal glucose reabsorption (proximal tubule)" },
          { "id": "dpp4mech", "label": "Prevents incretin breakdown" }
        ],
        "correct": ["true"],
        "explanation": "AMPK activation reduces hepatic glucose output and improves insulin sensitivity; it does not stimulate insulin secretion or affect SGLT2/DPP-4."
      },
      {
        "id": "adrs",
        "title": "Important adverse reactions",
        "prompt": "Select ALL clinically important adverse reactions of metformin.",
        "type": "multi",
        "options": [
          { "id": "gi", "label": "GI upset (nausea/diarrhoea), metallic taste" },
          { "id": "lactic", "label": "Lactic acidosis (rare; risk ↑ in renal/hepatic failure or hypoxia)" },
          { "id": "b12", "label": "Vitamin B12 deficiency with long-term use" },
          { "id": "hypo", "label": "Hypoglycaemia (monotherapy)" },
          { "id": "weightGain", "label": "Weight gain" }
        ],
        "correct": ["gi", "lactic", "b12"],
        "explanation": "GI effects are common; rare lactic acidosis is the key serious risk; B12 can fall over time. Metformin alone does not usually cause hypoglycaemia and does not cause weight gain."
      },
      {
        "id": "interactions",
        "title": "Important drug–drug/intervention interactions",
        "prompt": "Select ALL interactions of concern with metformin.",
        "type": "multi",
        "options": [
          { "id": "contrast", "label": "Iodinated contrast in patients with renal impairment" },
          { "id": "alcohol", "label": "Excess alcohol use" },
          { "id": "cimet", "label": "Cimetidine (competition for renal tubular secretion)" },
          { "id": "warfarin", "label": "Warfarin" },
          { "id": "ppi", "label": "Proton-pump inhibitors" }
        ],
        "correct": ["contrast", "alcohol", "cimet"],
        "explanation": "Contrast and alcohol can precipitate lactic acidosis; cimetidine can raise metformin levels by reducing renal secretion. Warfarin/PPIs are not key metformin interactions."
      }
    ]
  }
]
